Abstracts Archive - Page 997 of 2607 - ACR Meeting Abstracts

Abstract Number: 853 • 2019 ACR/ARP Annual Meeting
Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis
Rosalinde Stal¹, Floris van Gaalen ¹, Alexandre Sepriano ¹, Jürgen Braun ², Monique Reijnierse ¹, Désirée van der Heijde ¹ and Xenofon Baraliakos ³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, ³Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Inflammation and new bone formation in the axial skeleton are characteristic features of radiographic axial spondyloarthritis (r-axSpA). Facet joints are frequently involved in r-axSpA…
Abstract Number: 854 • 2019 ACR/ARP Annual Meeting
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Elena Nikiphorou¹, Sofia Ramiro ², Alexandre Sepriano ³, Adeline Ruyssen Witrand ⁴, Robert B.M. Landewé ⁵ and Désirée van der Heijde ³, ¹King's College London, London, United Kingdom, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology center, Pierre Paul Riquet Hospital, CHU of Toulouse, Paul Sabatier University, UMR 1027, Inserm, France, Toulouse, France, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE)…
Abstract Number: 855 • 2019 ACR/ARP Annual Meeting
Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?
Xenofon Baraliakos¹, Anna Ghadir ², Martin Fruth ², Uta Kiltz ³ and Jürgen Braun ⁴, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Radiology Herne, Herne, Germany, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Classification of patients as having axial spondyloarthritis (axSpA) by the imaging arm of the ASAS criteria relies partly on the detection of bone marrow…
Abstract Number: 856 • 2019 ACR/ARP Annual Meeting
MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
Ulrich Weber¹, Anne Grethe Jurik ², Anna Zejden ², Ejnar Larsen ³, Steen Hylgaard Jørgensen ⁴, Kaspar Rufibach ⁵, Christian Schioldan ⁶ and Søren Schmidt-Olsen ⁷, ¹Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ²Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Radiology, North Denmark Regional Hospital, Hjørring, Denmark, ⁴Center for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark, ⁵Division of Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland, ⁶Department of Physiotherapy, Clinic Benefit, Frederikshavn, Denmark, ⁷Department of Rheumatology and Sports Medicine, North Denmark Regional Hospital, Hjørring, Denmark
Background/Purpose: Low grade bone marrow edema (BME) on magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is challenging the discrimination between patients with early…
Abstract Number: 857 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
Xinran Yuan ¹, Dandan Wang ¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely…
Abstract Number: 858 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
Saira Sheikh¹, Morton Scheinberg ², Cheng-Chung Wei ³, Dana Tegzova ⁴, William Stohl ⁵, Ricardo Acayaba de Toledo ⁶, Tamara Mucenic ⁷, Mauricio Abello Banfi ⁸, Kathleen Maksimowicz-McKinnon ⁹, Carlos Abud-Mendoza ¹⁰, Sandra Navarra ¹¹, Mercedes Garcia ¹², Ignacio Garcia-De La Torre ¹³, Josep Ordi Ros ¹⁴, Roger Abramino Levy ¹⁵, Damon L Bass ¹⁵, Jorge Ross Terrés ¹⁶, Raj Punwaney ¹⁶, Julia Harris ¹⁷, Alireza Nami ¹⁸, Amy Pierce ¹⁹, Kevin Thorneloe ²⁰, Beulah Ji ¹⁷ and David Roth ¹⁶, ¹University of North Carolina, Chapel Hill, NC, ²Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil, ³Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ⁷Hospital Moinhos Angeles de Vento, Porto Alegre, Brazil, ⁸Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁹Henry Ford Hospital, Wayne State University, Detroit, MI, ¹⁰Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²Hospital San Martín, La Plata, Argentina, ¹³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ¹⁴Hospital Vall d'Hebron, Barcelona, Spain, ¹⁵GlaxoSmithKline, Collegeville, PA, ¹⁶GSK, Collegeville, PA, ¹⁷GSK, Uxbridge, Middlesex, United Kingdom, ¹⁸Joint Muscle Medical Care and Research Institute, Charlotte, NC, ¹⁹ViiV Healthcare, Research Triangle Park, NC, ²⁰GSK, Collegeville, NC
Background/Purpose: Belimumab (BEL), approved in active, autoantibody-positive SLE, has demonstrated a positive efficacy/safety profile while suggesting potential for steroid sparing and reduced organ damage accrual.…
Abstract Number: 859 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Chi Chiu Mok¹, Ling Yin Ho ², Shirley Ying ³, Woon Leung Ng ⁴ and Man Chi Leung ⁴, ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Princess Margaret Hospital, Hong Kong, Hong Kong, ⁴United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the 10-year outcome of patients with lupus nephritis (LN) treated with combined prednisolone with mycophenolate mofetil (MMF) or tacrolimus (TAC) as induction…
Abstract Number: 860 • 2019 ACR/ARP Annual Meeting
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
Luiz Sergio Guedes Barbosa ¹, Amit Saxena ², Ellen M Ginzler ³, Richard Furie⁴, David D'Cruz ⁵, Susan Burriss ⁶, Jennifer Gilbride ⁷, Michelle Miller ⁶, James Groark ⁶, David Roth ⁶ and Beulah Ji ⁸, ¹NUTEC - Núcleo de Terapia Especializada em Cancerologia, Cuiaba, Brazil, ²New York University School of Medicine, New York, NY, ³State University of New York Downstate Medical Center, Brooklyn, NY, ⁴Northwell Health, Great Neck, NY, ⁵The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁶GSK, Collegeville, PA, ⁷GSK, Stevenage, Hertfordshire, United Kingdom, ⁸GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Black patients have more severe SLE and more frequent lupus nephritis vs other racial groups. Efficacy and safety of intravenous (IV) belimumab was demonstrated…
Abstract Number: 861 • 2019 ACR/ARP Annual Meeting
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Victoria Werth¹, Bevra Hahn ², George Tsokos ³, Shawn Rose ⁴, Kaiyin Fei ⁴, Yun Gregan ⁴, Robert Gordon ⁴, Kim Hung Lo ⁴ and Ronald van Vollenhoven ⁵, ¹Hospital of the Univ of PA and Veteran’s Administration Med Center, Philadelphia, PA, ²University of California, Los Angeles, CA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Ustekinumab (UST), an anti-IL-12/23 p40 monoclonal antibody, showed significantly greater improvement at week (wk) 24 compared with placebo (PBO) in Systemic Lupus Erythematosus Disease…
Abstract Number: 862 • 2019 ACR/ARP Annual Meeting
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
Viktoria Hermann¹, Anastas Batalov ², Svetlana Smakotina ³ and Peter Cornelisse ¹, ¹Idorsia, Allschwil, Switzerland, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Kemerovo Regional Clinical Hospital, Kemerovo, Russia
Background/Purpose: Aberrantly activated T- and B-lymphocytes play a major pathophysiological role in SLE. Cenerimod, a potent, selective sphingosine-1-phosphate 1 receptor modulator, blocks the egress of…
Abstract Number: 863 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial
Dinesh Khanna¹, Erica Bush ², Vivek Nagaraja ², Andrew Koenig ³, Puja Khanna ⁴, Amber Young ⁵, Jeffrey Moore ⁶, David Fox ⁶ and Robert Lafyatis ⁷, ¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Collegeville, ⁴University of Michigan Medical School, Ann Arbor, ⁵University of Michigan, Ann Arbot, ⁶University of Michigan, Ann Arbor, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Tofacitinib (TOFA) is a potent pan inhibitor of the Janus Kinase (JAK) family of kinases with a high degree of selectivity against JAK1 and…
Abstract Number: 864 • 2019 ACR/ARP Annual Meeting
Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Robert Spiera ¹, Dana Orange ², Cynthia Magro ³, Yaxia Zhang ⁴, Jackie Finik ⁵ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The Combined Response Index in Systemic Sclerosis (CRISS) is a composite outcome measure provisionally endorsed by the American College of Rheumatology for use in…
Abstract Number: 865 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert Spiera¹, Laura Hummers ², Lorinda Chung ³, Tracy Frech ⁴, Robyn Domsic ⁵, Vivien Hsu ⁶, Daniel Furst ⁷, Jessica Gordon ¹, Madeline Myers ⁸, Robert W Simms ⁹, Elizabeth Lee ¹⁰, Scott Constantine ¹⁰, Nancy Dgetluck ¹⁰, Bradley Bloom ¹⁰ and Barbara White ¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ³Stanford, Palo Alto, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁷University of California, Los Angeles, CA, ⁸University of Texas, Houston, Houston, TX, ⁹Boston University, Boston, MA, ¹⁰Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models…
Abstract Number: 866 • 2019 ACR/ARP Annual Meeting
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
Edward Stern ¹, Lauren Host ¹, K. Jane Escott ², Peter Gilmour ², Ivy Wanjiku ³, Rachel Ochiel ³, Aine Burns ¹, Robert Unwin ¹, Voon Ong ⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²AstraZeneca, London, United Kingdom, ³Royal Free Hospital, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) causes scleroderma renal crisis (SRC) and chronic kidney disease (CKD). A previous open label trial of bosentan suggested possible benefit for…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].